{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:44:04Z","timestamp":1792557844991,"version":"4.5.0"},"reference-count":60,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,1,16]]},"DOI":"10.18632\/oncotarget.28551","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T06:35:36Z","timestamp":1705386936000},"page":"1-18","source":"Crossref","is-referenced-by-count":18,"title":["ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines"],"prefix":"10.18632","volume":"15","author":[{"given":"Mathew","family":"Lozinski","sequence":"first","affiliation":[{"name":"School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia"},{"name":"Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia"},{"name":"Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola A.","family":"Bowden","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia"},{"name":"Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira C.","family":"Graves","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia"},{"name":"Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia"},{"name":"Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fay","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia"},{"name":"Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia"},{"name":"Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia"},{"name":"GenesisCare, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan W.","family":"Day","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Stringer","sequence":"additional","affiliation":[{"name":"Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Tooney","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia"},{"name":"Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia"},{"name":"Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018","volume":"2","author":"Barnholtz-Sloan","year":"2021","journal-title":"Neuro Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"2","author":"Ellison","year":"2021","journal-title":"Neuro Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"7","author":"Khasraw","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"4","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis","volume":"1","author":"Brennan","year":"2020","journal-title":"Sci Rep"},{"key":"5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13402-021-00613-0","article-title":"DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets","volume":"4","author":"Tooney","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials","volume":"23","author":"Avan","year":"2018","journal-title":"J Cell Physiol"},{"key":"7","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-18-0569","article-title":"Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells","volume":"7","author":"Chalmers","year":"2018","journal-title":"Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"6","author":"Jackson","year":"2017","journal-title":"Mol Cell"},{"key":"9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"1","author":"Wilkinson","year":"2021","journal-title":"Cancer Discov"},{"key":"10","doi-asserted-by":"publisher","first-page":"TPS3153","DOI":"10.1200\/jco.2021.39.15_suppl.tps3153","article-title":"A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors","volume":"3","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"3","author":"Puc","year":"2021","journal-title":"Cancer Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"12","author":"Plummer","year":"2021","journal-title":"Br J Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-022-00406-0","article-title":"Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer","volume":"8","author":"Goddemeier","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"2","author":"Barroilhet","year":"2020","journal-title":"Lancet Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study","volume":"2","author":"Lau","year":"2021","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors","volume":"3","author":"Hare","year":"2020","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"1","author":"Rabkin","year":"2019","journal-title":"Nat Commun"},{"key":"18","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors","volume":"7","author":"Bindra","year":"2019","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.3390\/cancers14123015","article-title":"Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient\/ALT-Positive High-Grade Solid Tumors","volume":"1","author":"Rodriguez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12032-022-01657-4","article-title":"Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress","volume":"3","author":"Dutt","year":"2022","journal-title":"Med Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13014-018-1020-3","article-title":"ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration","volume":"1","author":"Daga","year":"2018","journal-title":"Radiat Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","article-title":"Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines","volume":"9","author":"Fine","year":"2006","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"publisher","first-page":"69185","DOI":"10.18632\/oncotarget.20193","article-title":"Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?","volume":"8","author":"Lenz","year":"2017","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"1","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"25","doi-asserted-by":"publisher","first-page":"e104036","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"3","author":"Huang","year":"2020","journal-title":"EMBO J"},{"key":"26","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"2","author":"Pommier","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1038\/s41598-019-41277-z","article-title":"A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma","volume":"9","author":"Lucas","year":"2019","journal-title":"Sci Rep"},{"key":"28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"46","author":"Sos","year":"2009","journal-title":"Nature"},{"key":"29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"2","author":"Tang","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying Drug Combination Synergy along Potency and Efficacy Axes","volume":"8","author":"Quaranta","year":"2019","journal-title":"Cell Syst"},{"key":"31","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer","volume":"2","author":"Thompson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment","volume":"2","author":"Ragulan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Tamayo","year":"2015","journal-title":"Cell Syst"},{"key":"34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"2","author":"Fitzgerald","year":"2019","journal-title":"Nat Rev Genet"},{"key":"35","doi-asserted-by":"publisher","first-page":"190156","DOI":"10.1098\/rsob.190156","article-title":"A consensus set of genetic vulnerabilities to ATR inhibition","volume":"9","author":"Durocher","year":"2019","journal-title":"Open Biol"},{"key":"36","doi-asserted-by":"publisher","first-page":"32396","DOI":"10.18632\/oncotarget.6136","article-title":"Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","volume":"6","author":"Curtin","year":"2015","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"publisher","first-page":"e57098","DOI":"10.1371\/journal.pone.0057098","article-title":"Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells","volume":"8","author":"Madhusudan","year":"2013","journal-title":"PLoS One"},{"key":"38","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1038\/s41598-022-09614-x","article-title":"Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma","volume":"1","author":"Bindra","year":"2022","journal-title":"Sci Rep"},{"key":"39","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/S0959-8049(22)01064-4","article-title":"ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis","volume":"17","author":"Ginzburg","year":"2022","journal-title":"Eur J Cancer"},{"key":"40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/1538-7445.am2019-369","article-title":"Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy","volume":"7","author":"Blaukat","year":"2019","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00001813-199701000-00013","article-title":"evaluation of temozolomide combined with X-irradiation","volume":"8","author":"Newlands","year":"1997","journal-title":"Anticancer Drugs"},{"key":"42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/s0360-3016(99)00539-8","article-title":"Survival of human glioma cells treated with various combination of temozolomide and X-rays","volume":"4","author":"Slotman","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/cells11071215","article-title":"Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment","volume":"1","author":"Tooney","year":"2022","journal-title":"Cells"},{"key":"44","doi-asserted-by":"publisher","first-page":"108080","DOI":"10.1016\/j.celrep.2020.108080","article-title":"Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses","volume":"3","author":"Greenberg","year":"2020","journal-title":"Cell Rep"},{"key":"45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-14-0099","article-title":"STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment","volume":"2","author":"Okada","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"1","author":"Rosenfeld","year":"2020","journal-title":"Nat Commun"},{"key":"47","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.18632\/oncotarget.28069","article-title":"Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma","volume":"1","author":"Tooney","year":"2021","journal-title":"Oncotarget"},{"key":"48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"3","author":"Lee","year":"2022","journal-title":"Ann Oncol"},{"key":"49","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","article-title":"Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them","volume":"12","author":"Massaad","year":"2022","journal-title":"Br J Cancer"},{"key":"50","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","article-title":"admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties","volume":"5","author":"Tang","year":"2012","journal-title":"J Chem Inf Model"},{"key":"51","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1038\/s41598-022-07247-8","article-title":"Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration","volume":"1","author":"Jursic","year":"2022","journal-title":"Sci Rep"},{"key":"52","doi-asserted-by":"publisher","first-page":"e0251998","DOI":"10.1371\/journal.pone.0251998","article-title":"High-dose drug heat map analysis for drug safety and efficacy in multi-spheroid brain normal cells and GBM patient-derived cells","volume":"1","author":"Nam","year":"2021","journal-title":"PLoS One"},{"key":"53","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"2","author":"Davis","year":"2017","journal-title":"Clin Cancer Res"},{"key":"54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12885-022-09197-w","article-title":"Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy","volume":"2","author":"Bowden","year":"2022","journal-title":"BMC Cancer"},{"key":"55","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"1","author":"Tang","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"56","doi-asserted-by":"publisher","first-page":"25523","DOI":"10.1038\/srep25523","article-title":"BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action","volume":"6","author":"Shelat","year":"2016","journal-title":"Sci Rep"},{"key":"57","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btaa826","article-title":"synergy: a Python library for calculating, analyzing and visualizing drug combination synergy","volume":"3","author":"Albert","year":"2021","journal-title":"Bioinformatics"},{"key":"58","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1038\/s41596-021-00615-0","article-title":"Analysis of clonogenic growth","volume":"1","author":"Lauber","year":"2021","journal-title":"Nat Protoc"},{"key":"59","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.12688\/F1000RESEARCH.12093.2","article-title":"BcbioRNAseq: R package for bcbio rna-seq analysis [version 2; peer review: 1 approved, 1 approved with reservations]","volume":"7","author":"Sui","year":"2018","journal-title":"F1000Research"},{"key":"60","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"1","author":"Anders","year":"2014","journal-title":"Genome Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T06:36:04Z","timestamp":1705386964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,16]]}},"alternative-id":["28551"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28551","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.02.565414","asserted-by":"object"}]},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}